An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorder.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Saredutant (Primary) ; Escitalopram
- Indications Major depressive disorder
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- 24 May 2016 Biomarkers information updated
- 28 Jun 2012 Lundbeck A/S added as associations and planned number of patients changed from 615 to 675 as reported in the European Clinical Trials Database record.
- 13 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov